Patent · US Active

Solid oral dosage form containing an enhancer

US8119159B2 · kind B2 · utility

109Cited by

69References

40Claims

0Family size

Assignee

Merrion Research III Limited · IE

Inventors

Kenneth Iain Cumming · Dublin, IE
Zebunissa Ramtoola · Dublin, IE
Thomas W. Leonard · Plattsburgh, US

Key dates

Filing date	Apr 7, 2006
Grant date	Feb 21, 2012
Priority date	—
Expiry date	Mar 14, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2846
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.